Our statistical analysis revealed a significant upregulation of TP53I11 expression in breast cancer tissues from DOX-treated patients compared to untreated controls, regardless of whether DOX was administered in combination or sequentially with cyclophosphamide (Figure 4J). This evidence concerns the gene TP53I11 and breast carcinoma.